Advertisement
Advertisement
BIVI
BioVie, Inc. Common Stock
1.10
USDSponsored
+0.10
+10.08%
Aug 10, 16:00 UTC -4
Closed
After-Market
1.09
-0.01
-0.45%
BIVI Earnings Reports
Positive Surprise Ratio
BIVI beat 8 of 13 last estimates.
62%
Next Report
In 3 Days
Date of Next Report
Aug 13, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.53
Implied change from Q3 26 (Revenue/ EPS)
--
/-24.29%
Implied change from Q4 25 (Revenue/ EPS)
--
/--
BioVie, Inc. Common Stock earnings per share and revenue
On May 11, 2026, BIVI reported earnings of -0.70 USD per share (EPS) for Q3 26, beating the estimate of -0.74 USD, resulting in a 5.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.22% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 3 analysts forecast an EPS of -0.53 USD, with revenue projected to reach -- USD, implying an decrease of -24.29% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were BioVie, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, BioVie, Inc. Common Stock reported EPS of -$0.70, beating estimates by 5.99%, and revenue of $0.00, 0% as expectations.
How did the market react to BioVie, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -2.22%, changed from $1.35 before the earnings release to $1.32 the day after.
When is BioVie, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 13, 2026.
What are the forecasts for BioVie, Inc. Common Stock's next earnings report?
Based on 3
analysts, BioVie, Inc. Common Stock is expected to report EPS of -$0.53 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement